EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti‐ ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP

Marie Robert iD, Arthur Mageau iD, Ygal Benhamou iD, François Provôt iD, Jehane Fadlallah iD, Lionel Galicier iD, Elie Azoulay iD, Hafid Ait-Oufella iD, Tomas Urbina iD, Pascale Poullin iD, Alain Wynckel iD, Coralie Poulain und 18 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.70005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Marie Robert und 29 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Référence des Microangiopathies Thrombotiques, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. Hauptthemen laut MEDLINE: ADAMTS13 Protein, Purpura, Thrombotic Thrombocytopenic, Autoantibodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current triplet regimens associating therapeutic plasma exchange (TPE), immunosuppression with corticosteroids and rituximab, and caplacizumab have dramatically improved the outcome of immune‐mediated thrombotic thrombocytopenic purpura (iTTP). However, nearly half of the patients require extended caplacizumab treatment (i.e., > 30 days) due to persistent ADAMTS13 deficiency, raising cost and tolerance concerns. Therefore, we investigated whether anti‐ADAMTS13 antibodies titer and their trajectory during the acute phase of the disease could predict ADAMTS13 improvement (i.e., activity ≥ 20% before day‐30 post‐TPE). From a cohort of 286 patients receiving the triplet regimen, we identified on diagnosis a cut‐off value for anti‐ADAMTS13 IgG antibodies of 90.5 U/mL, with a modest discriminating ability (AUC: 0.57) for predicting long‐term response, precluding its use to guide therapeutic strategies. Nonetheless, the analysis of anti‐ADAMTS13 IgG antibodies titer trajectory from diagnosis revealed that the proportion of iTTP patients with ADAMTS13 activity improvement was higher in patients who decreased (Dec+) their antibodies titer within the 7–14 days interval post‐TPE compared to those without decrease (Dec−) (65% vs. 25% of cases, respectively, p < 0.001), a finding confirmed in a validation cohort ( N = 51). These results highlight the possibility of intensifying immunosuppression in an early period post‐TPE to shorten time to ADAMTS13 activity recovery. Close monitoring of anti‐ADAMTS13 antibodies titer may guide immunomodulation strategies, including additional courses of B‐cell depleting agents when appropriate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAMTS13 ProteinPurpura, Thrombotic ThrombocytopenicAutoantibodiesHumansMaleFemaleMiddle AgedAdultPlasma ExchangeRituximabImmunoglobulin GAgedAdrenal Cortex HormonesSingle-Domain Antibodies

Stichwörter der Autor:innen

ADAMTS13caplacizumabimmune‐mediated thrombotic thrombocytopenic purpuraimmunosuppressionprognosisrituximab

Substanzen

ADAMTS13 ProteinADAMTS13 protein, humanAutoantibodiesRituximabImmunoglobulin GcaplacizumabAdrenal Cortex HormonesSingle-Domain Antibodies

Autor:innen und Institutionen

  • Centre de Référence des Microangiopathies Thrombotiques, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Département de Médecine Interne, Hôpital Bichat-Claude Bernard, HUPNVS, AP-HP. Université Paris Cité. Inserm UMR 1137 IAME, Team DESCID, Paris, France.
  • Département de Médecine Interne, CHU Charles Nicolle, Rouen, France.
  • Université de Normandie, UNIROUEN, INSERM U1096 EnVI, Rouen, France.
  • Service de Néphrologie, Hôpital Albert Calmette, Lille, France.
  • Service d'Immunologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

ORCID-Profile: Marie Robert, Arthur Mageau, Ygal Benhamou, François Provôt, Jehane Fadlallah, Lionel Galicier, Elie Azoulay, Hafid Ait-Oufella, Tomas Urbina, Pascale Poullin, Alain Wynckel, Nihal Martis, Pierre Perez, Virginie Rieu, Yahsou Delmas, Jean-Michel Halimi, Christelle Barbet, Valérie Chatelet, Jean-François Augusto, Mathieu Legendre, Olivier Moranne, Carole Philipponnet, Bérengère Cador, Raïda Bouzid, Bérangère S Joly, Agnès Veyradier, Paul Coppo

Förderung

  • French Ministry of Health

Zitieren

APA

Robert, M., Mageau, A., Benhamou, Y., Provôt, F., Fadlallah, J., Galicier, L., Azoulay, E., Ait-Oufella, H., Urbina, T., Poullin, P., Wynckel, A., Poulain, C., Martis, N., Perez, P., Rieu, V., Delmas, Y., Halimi, J. M., Barbet, C., Seguin, A., …, & French Reference Center for Thrombotic Microangiopathies (2025). Anti‐ ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP. American Journal of Hematology. https://doi.org/10.1002/ajh.70005

Vancouver

Robert M, Mageau A, Benhamou Y, Provôt F, Fadlallah J, Galicier L, et al. Anti‐ ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP. American Journal of Hematology. 2025. doi:10.1002/ajh.70005

BibTeX
@article{Robert2025,
  author = {Robert, Marie and Mageau, Arthur and Benhamou, Ygal and Provôt, François and Fadlallah, Jehane and Galicier, Lionel and Azoulay, Elie and Ait-Oufella, Hafid and Urbina, Tomas and Poullin, Pascale and Wynckel, Alain and Poulain, Coralie and Martis, Nihal and Perez, Pierre and Rieu, Virginie and Delmas, Yahsou and Halimi, Jean-Michel and Barbet, Christelle and Seguin, Amélie and Chatelet, Valérie and Augusto, Jean-François and Legendre, Mathieu and Moranne, Olivier and Philipponnet, Carole and Cador, Bérengère and Bouzid, Raïda and Joly, Bérangère S and Veyradier, Agnès and Coppo, Paul and French Reference Center for Thrombotic Microangiopathies, French Reference Center for Thrombotic Microangiopathies},
  title = {Anti‐ ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.70005}
}
Kostenlos starten →